File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection

TitleHepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection
Authors
Issue Date2007
PublisherAmerican Society for Microbiology. The Journal's web site is located at http://jcm.asm.org/
Citation
Journal Of Clinical Microbiology, 2007, v. 45 n. 12, p. 3942-3947 How to Cite?
AbstractA sensitive chemiluminescence enzyme immunoassay has been developed for hepatitis B virus (HBV) core-related antigen (HBcrAg) detection. We aimed to investigate the usefulness of HBcrAg measurement for monitoring chronic hepatitis B disease. HBcrAg levels were measured by a chemiluminescence enzyme immunoassay in 54 untreated patients and 39 patients treated with either entecavir or lamivudine. The HBcrAg concentration correlated positively with the levels of serum HBV DNA (r = 0.820), intrahepatic total HBV DNA (r = 0.700), and covalently closed circular DNA (cccDNA) (r = 0.664; for all, P values were <0.001). A higher HBcrAg concentration was associated with a greater proportion of hepatitis B core antigen immunostaining. Although the differences were not statistically significant, patients with higher Knodell necroinflammation and fibrosis scores tended to have higher serum HBcrAg concentration levels. In the treated patients, the logarithmic reduction in HBcrAg at week 48 correlated positively with the logarithmic reduction of serum HBV DNA, intrahepatic total HBV DNA, and cccDNA. Of the 31 patients with undetectable serum HBV DNA (<300 copies/ml) at the end of treatment, 20 (65%) still had detectable HBcrAg. A greater reduction in posttreatment HBcrAg concentration was associated with histological improvement and a decrease in hepatitis B core antigen immunostaining. HBcrAg concentrations of <40,000 kU/ml at baseline and <200 kU/ml at week 24 were associated with a higher chance of having undetectable HBV DNA at week 48. In conclusion, serum HBcrAg levels correlated with HBV virological markers and reflected the chronic hepatitis B disease activity in the liver. Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Persistent Identifierhttp://hdl.handle.net/10722/163134
ISSN
2015 Impact Factor: 3.631
2015 SCImago Journal Rankings: 2.151
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, DKHen_US
dc.contributor.authorTanaka, Yen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorMizokami, Men_US
dc.contributor.authorFung, Jen_US
dc.contributor.authorYuen, MFen_US
dc.date.accessioned2012-09-05T05:28:00Z-
dc.date.available2012-09-05T05:28:00Z-
dc.date.issued2007en_US
dc.identifier.citationJournal Of Clinical Microbiology, 2007, v. 45 n. 12, p. 3942-3947en_US
dc.identifier.issn0095-1137en_US
dc.identifier.urihttp://hdl.handle.net/10722/163134-
dc.description.abstractA sensitive chemiluminescence enzyme immunoassay has been developed for hepatitis B virus (HBV) core-related antigen (HBcrAg) detection. We aimed to investigate the usefulness of HBcrAg measurement for monitoring chronic hepatitis B disease. HBcrAg levels were measured by a chemiluminescence enzyme immunoassay in 54 untreated patients and 39 patients treated with either entecavir or lamivudine. The HBcrAg concentration correlated positively with the levels of serum HBV DNA (r = 0.820), intrahepatic total HBV DNA (r = 0.700), and covalently closed circular DNA (cccDNA) (r = 0.664; for all, P values were <0.001). A higher HBcrAg concentration was associated with a greater proportion of hepatitis B core antigen immunostaining. Although the differences were not statistically significant, patients with higher Knodell necroinflammation and fibrosis scores tended to have higher serum HBcrAg concentration levels. In the treated patients, the logarithmic reduction in HBcrAg at week 48 correlated positively with the logarithmic reduction of serum HBV DNA, intrahepatic total HBV DNA, and cccDNA. Of the 31 patients with undetectable serum HBV DNA (<300 copies/ml) at the end of treatment, 20 (65%) still had detectable HBcrAg. A greater reduction in posttreatment HBcrAg concentration was associated with histological improvement and a decrease in hepatitis B core antigen immunostaining. HBcrAg concentrations of <40,000 kU/ml at baseline and <200 kU/ml at week 24 were associated with a higher chance of having undetectable HBV DNA at week 48. In conclusion, serum HBcrAg levels correlated with HBV virological markers and reflected the chronic hepatitis B disease activity in the liver. Copyright © 2007, American Society for Microbiology. All Rights Reserved.en_US
dc.languageengen_US
dc.publisherAmerican Society for Microbiology. The Journal's web site is located at http://jcm.asm.org/-
dc.relation.ispartofJournal of Clinical Microbiologyen_US
dc.rightsJournal of Clinical Microbiology. Copyright © American Society for Microbiology.-
dc.subject.meshAdulten_US
dc.subject.meshDna, Viral - Blooden_US
dc.subject.meshEnzyme-Linked Immunosorbent Assay - Methodsen_US
dc.subject.meshFemaleen_US
dc.subject.meshGuanine - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshHepatitis B Core Antigens - Blooden_US
dc.subject.meshHepatitis B Virus - Chemistryen_US
dc.subject.meshHepatitis B, Chronic - Drug Therapy - Virologyen_US
dc.subject.meshHumansen_US
dc.subject.meshLamivudine - Therapeutic Useen_US
dc.subject.meshLiver - Pathology - Virologyen_US
dc.subject.meshLiver Cirrhosis - Pathologyen_US
dc.subject.meshLuminescent Measurements - Methodsen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNecrosis - Pathologyen_US
dc.subject.meshStatistics As Topicen_US
dc.titleHepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infectionen_US
dc.typeArticleen_US
dc.identifier.emailWong, DKH:danywong@hku.hken_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.emailFung, J:jfung@sicklehut.comen_US
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_US
dc.identifier.authorityWong, DKH=rp00492en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.identifier.authorityFung, J=rp00518en_US
dc.identifier.authorityYuen, MF=rp00479en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1128/JCM.00366-07en_US
dc.identifier.pmid17942661-
dc.identifier.scopuseid_2-s2.0-37249092014en_US
dc.identifier.hkuros149094-
dc.identifier.hkuros144304-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-37249092014&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume45en_US
dc.identifier.issue12en_US
dc.identifier.spage3942en_US
dc.identifier.epage3947en_US
dc.identifier.isiWOS:000251630000012-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridWong, DKH=7401535819en_US
dc.identifier.scopusauthoridTanaka, Y=7405315865en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridMizokami, M=7103318255en_US
dc.identifier.scopusauthoridFung, J=23091109300en_US
dc.identifier.scopusauthoridYuen, MF=7102031955en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats